Breast cancer therapy Ibrance available at Walgreens Specialty Pharmacy

DEERFIELD, Ill. — Walgreens on Thursday announced that Ibrance (palbociclib) is immediately available through Walgreens Specialty Pharmacy for those requiring access to advanced, metastatic breast cancer therapy. Walgreens Specialty Pharmacy was selected by Pfizer as one of a group of pharmacies to dispense Ibrance for use, in combination with letrozole, as initial endocrine-based therapy for postmenopausal women with ER+/HER2- advanced breast cancer. Walgreens Specialty Pharmacy also has access to letrozole, the required accompaniment drug.

 

“Through our integrated clinical and specialty distribution assets, we deliver comprehensive and collaborative patient care for those within the breast cancer community and are pleased to be able to better serve patients requiring this anti-cancer medication,” stated Mike Ellis, Walgreens corporate VP, specialty and infusion pharmacy.

 

Working collaboratively with oncology providers, Walgreens Specialty Pharmacy delivers comprehensive patient care for those managing cancer therapies. Patients benefit from Walgreens access to limited distribution drugs, as well as a number of support services. These include help verifying insurance and identifying financial assistance options and supportive nutrition care through Walgreens infusion services capabilities.

 

Ibrance is available at select Walgreens specialty, community and health system pharmacies.